<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330118</url>
  </required_header>
  <id_info>
    <org_study_id>2019_01</org_study_id>
    <secondary_id>2019-A02026-51</secondary_id>
    <nct_id>NCT04330118</nct_id>
  </id_info>
  <brief_title>Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome</brief_title>
  <acronym>DRESSEO</acronym>
  <official_title>Origin and Function of Eosinophilic Polynuclear During Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Société de Dermatologie Française</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société de Recherche en Dermatologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug Hypersensitivity Syndrome or DRESS for &quot;Drug Reaction with Eosinophilia and Systemic&#xD;
      Symptoms&quot; is a serious drug allergy which can be life-threatening for patients with serious&#xD;
      organ damage. The pathophysiology of DRESS is still not fully understood. In particular, no&#xD;
      study has focused on the characterization of eosinophils, while paradoxically eosinophilia is&#xD;
      one of the diagnostic criteria. Likewise, there is no data about the origin of eosinophils&#xD;
      and few data are available concerning immune polarization of T-cells or the involvement of&#xD;
      innate lymphoid cells type 2 in the recruitment of eosinophils. Our preliminary data on&#xD;
      increase activation markers membrane expression of cutaneous eosinophils suggest that this&#xD;
      approach could allow the identification of endotypes in which eosinophils are involved and&#xD;
      contribute to organ damages. The correlation between tissue infiltration of eosinophils and&#xD;
      their degree of activation would then justify the development of targeted therapeutic&#xD;
      strategies in DRESS syndrome (anti-IL-5 therapy?). The aim of the project is: 1) Evaluate the&#xD;
      activation status of circulating and cutaneous eosinophils in patients with DRESS compared&#xD;
      with drug induced maculopapular exanthema without or with eosinophilia (but do not fulfill&#xD;
      DRESS criteria) and healthy subjects; 2) Understand the pathophysiological mechanisms at the&#xD;
      origin of this eosinophilia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Activation status of circulating eosinophils by flow cytometry</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean fluorescence intensity of CCR3 and IL-5R markers</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Th2 polarized T cells</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of ILC2</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels (ELISA) of inflammatory markers</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the number of activated circulating eosinophils, area degranulation and severity of DRESS</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of extracellular granules (degranulation area and number / mm2) on skin biopsies</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NGS analysis of rearrangements of TCR (T cell receptor)</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Drug Hypersensitivity</condition>
  <condition>DRESS Syndrome</condition>
  <arm_group>
    <arm_group_label>20 patients with DRESS syndrome</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>20 patients with drug induced MPE with eosinophilia</arm_group_label>
    <description>patients with drug induced maculopapular exanthema (MPE) with eosinophilia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 patients with drug induced MPE without eosinophilia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>20 Healthy subjects</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Blood sample&#xD;
&#xD;
        -  Serum&#xD;
&#xD;
        -  peripheral blood mononuclear cell&#xD;
&#xD;
        -  skin biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with drug induced rash (DRESS, maculopapular exanthema) and healthy patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1 (DRESS): adult with a diagnosis of DRESS based on the following four criteria:&#xD;
&#xD;
          -  Cutaneous rash occurring at least 24 hours and at most 2 months after continuous&#xD;
             medication use&#xD;
&#xD;
          -  Fever over 38 degre celcius&#xD;
&#xD;
          -  At least one organ dysfunction among:&#xD;
&#xD;
          -  Lymphadenopathy&#xD;
&#xD;
          -  hepatitis&#xD;
&#xD;
          -  Pulmonary involvement&#xD;
&#xD;
          -  Cardiac involvement: myocarditis, pericarditis&#xD;
&#xD;
          -  Renal impairment&#xD;
&#xD;
          -  At least one of the following hematological anomalies:&#xD;
&#xD;
          -  Eosinophilia ≥ 500 / mm3 or ≥ 10% of absolute value&#xD;
&#xD;
          -  Lymphocytosis &gt; 5000 / mm3&#xD;
&#xD;
          -  Presence of atypical blood lymphocytes.&#xD;
&#xD;
          -  RegiSCAR Score ≥ 4&#xD;
&#xD;
        Groups 2 and 3 (Drug induced maculopapular exanthema without or with eosinophilia).&#xD;
&#xD;
          -  Adult with drug-induced rash&#xD;
&#xD;
          -  Without clinical criteria of severity defined by Djien among :&#xD;
&#xD;
          -  An evolution of more than 21 days&#xD;
&#xD;
          -  Associated visceral involvement.&#xD;
&#xD;
          -  Do not fulfill DRESS criteria&#xD;
&#xD;
        Group 2 (MPE without eosinophilia): blood eosinophils &lt; 500 / mm3&#xD;
&#xD;
        Group 3 (MPE with eosinophilia): blood eosinophils ≥ 500 / mm3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other cause of eosinophilia including cancer, blood disease before the introduction of&#xD;
             suspected molecule(s).&#xD;
&#xD;
          -  On going oral or local corticosteroid therapy, anti-leukotriene therapy (MONTELUKAST)&#xD;
             by the month preceding the study;&#xD;
&#xD;
          -  Anti-IgE therapy (OMALIZUMAB, LIGELIZUMAB), anti-IL-5 therapy (MEPOLIZUMAB,&#xD;
             BENRALIZUMAB) or anti-IL4 and / or anti-IL13 therapy (DUPILUMAB, TRALOKINUMAB) in the&#xD;
             6 months preceding the study.&#xD;
&#xD;
          -  Any pregnant or lactating woman.&#xD;
&#xD;
          -  Contraindication related to the blood volume taken for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine Staumont-Salle, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Delphine Staumont-Salle, MD,PhD</last_name>
    <phone>0320444193</phone>
    <phone_ext>+33</phone_ext>
    <email>delphine.salle@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH LENS</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hop Claude Huriez Chr Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DRESS syndrome</keyword>
  <keyword>Drug hypersensitivity</keyword>
  <keyword>eosinophils</keyword>
  <keyword>allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Hypersensitivity Syndrome</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Drug Hypersensitivity</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

